Controlled trial of thyrotropin releasing hormone in amyotrophic lateral sclerosis

Michael H. Brooke, Julaine M. Florence, Scott L. Heller, K. K. Kaiser, Daniel Phillips, Allen Gruber, Debbie Babcock, J. Philip Miller

Research output: Contribution to journalArticlepeer-review

52 Scopus citations


A double-blind controlled trial of thyrotropin releasing hormone (TRH) 150 mg IM daily in 30 patients with amyotrophic lateral sclerosis is reported. The drug/placebo was administered for 2 months, followed by a 2-month “wash-out.” Evaluation of strength, functional ability, and respiratory functions was performed. A temporary increase in the strength of some muscles was detected following the administration of TRH, but no change in functional performance was noted. Neither the patients nor the investigators believed the effects were of any marked clinical significance. The course of the illness was not altered.

Original languageEnglish
Pages (from-to)146-151
Number of pages6
Issue number2
StatePublished - Feb 1986


Dive into the research topics of 'Controlled trial of thyrotropin releasing hormone in amyotrophic lateral sclerosis'. Together they form a unique fingerprint.

Cite this